QIAGEN Net Profit Margin 2010-2023 | QGEN
Current and historical net profit margin for QIAGEN (QGEN) from 2010 to 2023. Net profit margin can be defined as net Income as a portion of total sales revenue. QIAGEN net profit margin for the three months ending March 31, 2023 was .
| QIAGEN Net Profit Margin Historical Data |
| Date |
TTM Revenue |
TTM Net Income |
Net Margin |
| 2023-03-31 |
$2.00B |
$0.35B |
17.66% |
| 2022-12-31 |
$2.14B |
$0.42B |
19.75% |
| 2022-09-30 |
$2.23B |
$0.46B |
20.80% |
| 2022-06-30 |
$2.26B |
$0.51B |
22.73% |
| 2022-03-31 |
$2.31B |
$0.54B |
23.27% |
| 2021-12-31 |
$2.25B |
$0.51B |
22.75% |
| 2021-09-30 |
$2.24B |
$0.60B |
26.61% |
| 2021-06-30 |
$2.19B |
$0.48B |
21.93% |
| 2021-03-31 |
$2.07B |
$0.45B |
21.74% |
| 2020-12-31 |
$1.87B |
$0.36B |
19.25% |
| 2020-09-30 |
$1.71B |
$0.19B |
11.21% |
| 2020-06-30 |
$1.61B |
$0.01B |
0.87% |
| 2020-03-31 |
$1.55B |
$-0.03B |
-2.00% |
| 2019-12-31 |
$1.53B |
$-0.04B |
-2.69% |
| 2019-09-30 |
$1.52B |
$-0.03B |
-1.65% |
| 2019-06-30 |
$1.51B |
$0.20B |
12.96% |
| 2019-03-31 |
$1.51B |
$0.19B |
12.48% |
| 2018-12-31 |
$1.50B |
$0.19B |
12.65% |
| 2018-09-30 |
$1.50B |
$0.09B |
5.95% |
| 2018-06-30 |
$1.48B |
$0.08B |
5.20% |
| 2018-03-31 |
$1.45B |
$0.05B |
3.71% |
| 2017-12-31 |
$1.42B |
$0.04B |
2.82% |
| 2017-09-30 |
$1.39B |
$0.09B |
6.41% |
| 2017-06-30 |
$1.36B |
$0.08B |
5.58% |
| 2017-03-31 |
$1.35B |
$0.08B |
6.16% |
| 2016-12-31 |
$1.34B |
$0.08B |
6.05% |
| 2016-09-30 |
$1.32B |
$0.12B |
9.39% |
| 2016-06-30 |
$1.30B |
$0.12B |
9.49% |
| 2016-03-31 |
$1.28B |
$0.13B |
9.91% |
| 2015-12-31 |
$1.28B |
$0.13B |
10.15% |
| 2015-09-30 |
$1.29B |
$0.10B |
8.05% |
| 2015-06-30 |
$1.31B |
$0.11B |
8.00% |
| 2015-03-31 |
$1.33B |
$0.11B |
8.53% |
| 2014-12-31 |
$1.34B |
$0.12B |
8.71% |
| 2014-09-30 |
$1.35B |
$0.15B |
11.23% |
| 2014-06-30 |
$1.33B |
$0.16B |
11.80% |
| 2014-03-31 |
$1.32B |
$0.07B |
5.48% |
| 2013-12-31 |
$1.30B |
$0.07B |
5.30% |
| 2013-09-30 |
$1.29B |
$0.05B |
3.65% |
| 2013-06-30 |
$1.27B |
$0.04B |
2.76% |
| 2013-03-31 |
$1.26B |
$0.12B |
9.51% |
| 2012-12-31 |
$1.25B |
$0.13B |
10.29% |
| 2012-09-30 |
$1.24B |
$0.09B |
7.33% |
| 2012-06-30 |
$1.23B |
$0.10B |
7.91% |
| 2012-03-31 |
$1.20B |
$0.10B |
8.08% |
| 2011-12-31 |
$1.17B |
$0.10B |
8.21% |
| 2011-09-30 |
$1.12B |
$0.13B |
11.78% |
| 2011-06-30 |
$1.11B |
$0.13B |
12.03% |
| 2011-03-31 |
$1.09B |
$0.14B |
12.79% |
| 2010-12-31 |
$1.09B |
$0.14B |
13.25% |
| 2010-09-30 |
$1.09B |
$0.15B |
13.94% |
| 2010-06-30 |
$1.08B |
$0.15B |
14.31% |
| 2010-03-31 |
$1.05B |
$0.15B |
13.87% |
| 2009-12-31 |
$1.01B |
$0.14B |
13.66% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.425B |
$2.142B |
|
QIAGEN N.V. is one of the world's leading providers of technologies and products for the separation, purification and handling of nucleic acids DNA/RNA. The company provides innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions. It has developed a comprehensive portfolio of proprietary, consumable products, and automated solutions for sample collection. Qiagen has subsidiaries several other countries with good sales potential. Segment Details Consumables: These are typically sample preparation or test kits that contain all the necessary reagents and buffers, and a manual including protocols and relevant background information. Automated Instruments: These automate the use of Sample & Assay Technologies into efficient solutions for a broad range of laboratory needs. Customer Classes: QIAGEN focuses on 4 principal segments or customer classes for sample and assay technologies:? Molecular Diagnostics, Applied Testing, Pharma and Academia.
|
